Last reviewed · How we verify
Generic latanoprost
Generic latanoprost is a Prostaglandin F analog Small molecule drug developed by CHU de Quebec-Universite Laval. It is currently FDA-approved for Open-angle glaucoma, Ocular hypertension.
Latanoprost is a prostaglandin F analog that binds to prostaglandin F receptors in the eye to increase uveoscleral outflow of aqueous humor, thereby lowering intraocular pressure.
Generic latanoprost is a small molecule that acts as a prostanoid FP receptor agonist, targeting the Prostaglandin F2-alpha receptor. It is used to treat conditions such as Primary Open Angle Glaucoma, Ocular Hypertension, and Elevated Intraocular Pressure.
At a glance
| Generic name | Generic latanoprost |
|---|---|
| Sponsor | CHU de Quebec-Universite Laval |
| Drug class | Prostaglandin F analog |
| Target | Prostaglandin F receptor (FP receptor) |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Latanoprost acts as a selective agonist of the prostaglandin F (FP) receptor, primarily located on the ciliary muscle bundle and trabecular meshwork of the eye. By activating these receptors, it enhances drainage of aqueous humor through the unconventional uveoscleral pathway, reducing intraocular pressure. This mechanism makes it effective for treating glaucoma and ocular hypertension.
Approved indications
- Open-angle glaucoma
- Ocular hypertension
Common side effects
- Conjunctival hyperemia
- Iris pigmentation increase
- Eyelash growth (hypertrichosis)
- Eye irritation/discomfort
- Periocular skin pigmentation
Key clinical trials
- Prospective, Double-masked, Randomized, Multi-center, Active-controlled, Parallel-group, 3-month Study Assessing the Safety & Ocular Hypotensive Efficacy of TC-002 Ophthalmic Solution Compared to Latanoprost Ophthalmic Solution 0.005% in Subjects With Elevated Intraocular Pressure (PHASE3)
- Efficacy of the Brand-name Latanoprost and One of Its Generic Version in Primary Open Angle Glaucoma and Ocular Hypertension (PHASE4)
- Latanoprost Versus Tafluprost: 24-hour Intraocular Pressure (IOP) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Generic latanoprost CI brief — competitive landscape report
- Generic latanoprost updates RSS · CI watch RSS
- CHU de Quebec-Universite Laval portfolio CI
Frequently asked questions about Generic latanoprost
What is Generic latanoprost?
How does Generic latanoprost work?
What is Generic latanoprost used for?
Who makes Generic latanoprost?
What drug class is Generic latanoprost in?
What development phase is Generic latanoprost in?
What are the side effects of Generic latanoprost?
What does Generic latanoprost target?
Related
- Drug class: All Prostaglandin F analog drugs
- Target: All drugs targeting Prostaglandin F receptor (FP receptor)
- Manufacturer: CHU de Quebec-Universite Laval — full pipeline
- Therapeutic area: All drugs in Ophthalmology
- Indication: Drugs for Open-angle glaucoma
- Indication: Drugs for Ocular hypertension
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing